Utah Medical Products (UTMD) furnishes Q4 and 2025 financial data

Rhea-AI Filing Summary

Utah Medical Products, Inc. furnished an update on its business by providing financial information for the three and twelve months ended December 31, 2025, in a press release dated January 29, 2026. The press release, attached as Exhibit 99.1, also contains forward-looking statements about 2025 and beyond.

The company submitted this information under a current report, stating that the material is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.

0000706698 false 0000706698 2026-01-29 2026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 29, 2026

UTAH MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
UTAH		000-12575		87-0342734
(State or other jurisdiction of		(Commission File Number)		(IRS Employer
incorporation or organization)				Identification No.)
7043 South 300 West
Midvale, Utah				84047
(Address of principal executive offices)				(Zip code)
Registrant’s telephone number, including area code:				Phone: (801) 566-1200
n/a
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
	Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

ITEM 2.02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated January 29, 2026.  

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS

The following is filed as an exhibit to this report:  

Exhibit Number*		Title of Document		Location
Item 99.1		Financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated January 29, 2026.
				This filing

_______________________________________

*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	UTAH MEDICAL PRODUCTS, INC.
Dated: January 29, 2026	By:	/s/ Kevin L. Cornwell
		Kevin L. Cornwell, Chief Executive Officer

FAQ

What did Utah Medical Products (UTMD) disclose in its January 29, 2026 8-K?

Utah Medical Products furnished financial information for the three and twelve months ended December 31, 2025. The data appears in a January 29, 2026 press release attached as Exhibit 99.1, which also includes forward-looking statements about 2025 and beyond.

Where can investors find Utah Medical Products’ Q4 and full-year 2025 financial details?

The financial details are contained in a press release dated January 29, 2026, attached as Exhibit 99.1. That exhibit includes information for the three and twelve months ended December 31, 2025 and related forward-looking statements about the company’s future periods.

Are the financial statements in Utah Medical Products’ January 2026 8-K considered filed with the SEC?

No. The company states that the information in the report, including Exhibit 99.1, is being furnished under Item 2.02. It is not deemed filed for Exchange Act Section 18 purposes and is not automatically incorporated into other securities filings.

What exhibit is attached to Utah Medical Products’ January 29, 2026 8-K?

The 8-K includes Exhibit 99.1, described as financial information for Utah Medical Products for the three and twelve months ended December 31, 2025. The exhibit also contains forward-looking statements presented in a press release dated January 29, 2026.

Does Utah Medical Products’ January 2026 8-K include forward-looking statements?

Yes. The company notes that Exhibit 99.1 contains forward-looking statements relating to 2025 and beyond. These statements are part of the press release dated January 29, 2026 that accompanies the financial information for the three and twelve months ended December 31, 2025.